ABSTRACT: The study objective was to determine if cattle health and performance comparing a targeted bovine respiratory disease (BRD) control program based on individualized risk prediction generated by a novel technology (Whisper On Arrival) was superior to a negative control (no metaphylaxis) yet no different than a positive control (conventional BRD control; 100% application). Across four study sites, auction market-derived beef calves were randomly allocated to one of four BRD control treatment groups: 1) Negative control (Saline), 2) Positive control (Tildipirosin [TIL] to 100% of the group), 3) Whisper-high (±TIL based on conservative algorithm threshold), and 4) Whisper-low (±TIL based on aggressive algorithm threshold). Within either Whisper On Arrival group, only calves predicted to be above the algorithm threshold by the technology (determined a priori) were administered TIL leaving the remainder untreated. Cattle were followed to either a short-term timepoint (50 or 60 d; health outcomes, all sites; feed performance outcomes, two sites) or to closeout (two sites). Data were analyzed as a completely randomized block design separately at each site. Across all sites, BRD control antibiotic use was reduced by 11% to 43% between the two Whisper On Arrival treatment groups compared to the positive control. The positive control and both Whisper On Arrival groups reduced \( P \leq 0.05 \) BRD morbidity compared to negative controls at both the short-term timepoint at three of the four sites and at closeout at one of two sites. The positive control and both Whisper-managed groups had improved \( P \leq 0.05 \) average daily gain (ADG), dry-matter intake (DMI), and feed efficiency compared to negative controls at the short-term timepoint at one of two sites. At closeout, the positive control and both Whisper-managed groups improved \( P \leq 0.05 \) ADG (deads-in) compared to the negative control at one of the two sites. At one of two sites, the positive control and the Whisper-high group displayed an improvement \( P \leq 0.05 \) in hot carcass weight compared to the negative control. The Whisper On Arrival technology maintained the benefits of a conventional BRD control program yet reduced BRD control antibiotic use by 11% to 43%. This technology maintained the benefits of a conventional BRD control program while reducing antibiotic costs to the producer and supporting judicious antimicrobial use.

Key words: bovine respiratory disease complex, cattle, feedlot, metaphylaxis, Whisper

© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society of Animal Science.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

doi: 10.1093/tas/txab081
INTRODUCTION

Bovine respiratory disease (BRD) is a disease complex encompassing animal, environment, and pathogen-related factors (Apley, 2006; Taylor et al., 2010). Due to numerous stress-related events, the incidence of BRD in the beef industry increases after weaning and impacts profitability due to elevated treatment costs, reduced weight gain, reduced feed efficiency, negative carcass outcomes, and increased mortality (Gardner et al., 1999; Nickell et al., 2008; Van Donkersgoed et al., 2008a). Numerous management practices are put in place within all segments of the beef industry to reduce the risk of BRD and its negative downstream impact (Taylor et al., 2010). One specific practice, BRD control (i.e., metaphylaxis) is a common management practice that reflects the administration of an antibiotic to all cattle within a targeted group identified as being of elevated risk of developing BRD (Nickell and White, 2010). These populations are visibly healthy but contain individual animals possibly experiencing subclinical disease as well as healthy animals with a high probability of downstream disease development. The decision to administer an antibiotic labeled for BRD control to a population of calves is dependent upon exposure to risk factors (e.g., procurement location(s), body weight [BW], travel distance, weather events/variation, unknown prior vaccination status, and farms of origin) previously shown to be associated with an increased risk of developing BRD during the feeding period (Babcock et al., 2010, 2013a; Cernicchiaro et al., 2012a, 2012b, 2012c).

The current methodology of BRD control (i.e., administration of an antibiotic to 100% of calves within a targeted cohort) is a highly efficacious management practice repeatedly shown to reduce the negative impact of BRD among populations with exposure to known risk factors (Nickell and White, 2010). Numerous clinical trials reflecting decades of study data were recently compiled by meta-analysis and reported that injectable antibiotics (labeled for BRD control therapy) reduce the risk of BRD morbidity 1.5-fold on average compared to the placebo (O’Connor et al., 2019). These outcomes subsequently are translated into economic value for the producer. Dennis et al. (2018) recently estimated that the practice of BRD control generates a net return of at least $532 million dollars to the U.S. beef industry.

Although efficacious, current BRD control practices involve the administration of an antibiotic to all individual calves within a defined group due to the inability to visually discern which individual calves may or may not benefit from BRD control therapy. Dedonder and Apley (2015) estimated that five calves must receive BRD control therapy in order to prevent one acute case of BRD. These results suggest, on average, that conventional BRD control antibiotics may be applied in excess to incoming cohorts of calves. The use of antimicrobials in bovine production can be costly to the producer and that cost is amplified (and value subsequently lost) when administered to animals without the possibility of value in return. Additionally, antibiotic use in animal agriculture is increasingly under pressure by human healthcare entities and regulatory bodies (Baptiste and Kyvsgaard, 2017; FDA, 2018; CDC, 2019). Prior efforts to reduce the economic impact of BRD control drug use have focused on the administration of the antibiotic to animals that display a rectal temperature exceeding a specific threshold (i.e., “temp and treat”). In contrast to traditional BRD control programs, this approach is designed to “diagnose” BRD at the specific time the animal is passing through the chute. However, prior research has shown a “temp and treat” program to be inferior to a conventional BRD control program (Vogel et al., 1998). In addition, forgoing BRD control therapy to animals that could benefit from its application raises animal welfare concerns among veterinarians (Dean, 2011).

In contrast to the above issues, the ideal scenario would be to maintain BRD control antibiotic application but evolve the practice from group application to one that targets only individual animals at elevated risk for developing BRD. This scenario may optimize the BRD control practice for the producer and provide objective justification for this BRD management practice to the end consumer.

The Whisper On Arrival system is a chute-side technology developed to predict the risk of BRD manifestation among individual calves at the time of arrival to a backgrounding, stocker, or feedlot production system. The technology leverages four data points: heart sounds, lung sounds, body temperature, and BW. The heart and lung data are collected by a patented sound-collection device that is placed (by the user) on the right side of the calf’s thorax just caudal to the right humero-radial joint. Those data are wirelessly transmitted to the chute-side software application. The calf’s rectal temperature and BW are currently hand-entered into the software application. Those data are then analyzed by a proprietary machine-learning algorithm to provide the user with a “Treat” (individual calves that are to receive BRD
control therapy) or “Do Not Treat” (individual calves that are left untreated) outcome.

The objective of this study was to compare health and performance outcomes among feedlot cattle managed by the following BRD control strategies: a targeted BRD control program based on individualized risk prediction generated by the Whisper On Arrival technology but at two different algorithm thresholds including 1) a conservative threshold targeted to reduce BRD control drug administration (compared to the positive control) yet administer BRD control therapy to the majority of animals and 2) an aggressive threshold designed to further reduce BRD control drug administration (i.e., a negative control; 0% application to the targeted population) and 3) a conventional BRD control drug practice (i.e., a positive control; 100% application to the targeted population).

MATERIALS AND METHODS

This multisite study was a joint effort among Merck Animal Health, Cactus Research (CR), AgriResearch Center (ARC), Bos Technica Research Services, Inc. (BT), and Midwest Veterinary Services, Inc. (MVS). Institutional Animal Care and Use Committee (IACUC) approval was not obtained at CR, ARC, and BT. However, IACUC approval was obtained by the researchers at the MVS study site. However, all sites followed the guidelines stated in the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching (FASS, 2010).

Sample Population Description

Four separate clinical trials were executed at four independent sites. Study locations consisted of two sites in Texas (TX-1 and TX-2), one site in Oklahoma (OK), and one site in Nebraska (NE). At each of the four sites, the same study protocol was utilized that reflected the same four treatment groups incorporated into a completely randomized block design.

Across all four sites, the targeted sample population included auction market-derived steer calf lots considered by each site to be “medium” or “high-risk” for development of BRD based upon risk factors previously identified to be associated with an increased risk of BRD development (Cernicchiaro et al., 2012a, 2012b, 2012c; Babcock et al., 2013a). Upon meeting these criteria, cattle were procured by all sites through standard industry channels. At arrival, only calves with a BRD clinical illness score (CIS) of ≤ 1 (Table 1) were eligible for study enrollment (Perino and Apley, 1998). Conversely, calves displaying BRD CISs of ≥ 2 or clinical signs of other infectious/noninfectious syndromes were not eligible for study enrollment.

On-Arrival Processing, Randomization, and Animal Monitoring

Within 72 h post-arrival, each respective lot was administered a processing regimen consisting of the following products: a modified-live viral vaccine (Vista Once SQ; Merck Animal Health, Madison, NJ; 2 mL per animal), a multivalent clostridium vaccine (Vision 8; Merck Animal Health; 2 mL per animal), and an oral deworming agent (Safe-Guard suspension 10%, Merck Animal Health; 5 mg/kg BW). Each calf received an ear tag with a unique visual identification number.

In addition to the above products, each calf received a steroid implant that reflected the duration of animal ownership at each site. Calves at TX-1 were administered a 36 mg Zeranol implant at arrival (Ralgro, Merck Animal Health). Calves at TX-2 were administered an 80 mg trenbolone acetate (TBA) and 16 mg estradiol (E₂) implant at arrival (Revalor IS, Merck Animal Health) and were reimplanted on Day 80 with a 200 mg TBA and 20 mg E₂ implant (Revalor-200, Merck Animal Health). Calves at OK received a 200 mg TBA and 40 mg E₂ implant at arrival (Revalor XS, Merck Animal Health). Calves enrolled at the MVS site received a 200 mg TBA and 40 mg E₂ implant at

| CIS   | Observed behavior                                                                 |
|-------|----------------------------------------------------------------------------------|
| 0     | • Bright, alert, responsive  
|       | • No abnormal clinical signs  
| 1     | • Noticeable depression  
|       | • May stand isolated with head down, ears drooping, but responsive to stimulation.  
| 2     | • Moderate depression  
|       | • May remain recumbent or stand isolated with head down, depression obvious when stimulated  
|       | • May stumble if forced to trot  
|       | • Noticeable dyspnea with gauntness and nasal/ocular discharges  
| 3     | • Severe depression  
|       | • Head carried low with ears drooping. Eyes dull, possible excess salivation/lacrimation  
|       | • Pronounced dyspnea and gauntness. Mouth breathing. Nasal and ocular discharges  
| 4     | • Moribund and able to rise  |
arrival (Revalor XS, Merck Animal Health). At each site, implants were administered subcutaneously in the posterior aspect of the respective animal’s ear.

At each site, an 8 s sound consisting of individual heart and lung sounds were collected by a computer-aided auscultation system (Whisper Veterinary Stethoscope; DeDonder, 2010; Zeineldin, 2016; Baruch et al., 2019). Sounds were collected on the cranio-ventral side of the right thorax just caudal to the calf’s humero-radial joint. In addition to lung and heart sounds, body temperature (obtained via rectal thermometer) and BW data were collected on each calf. The composited data were then analyzed by the Whisper On Arrival software. At each site, both the rectal thermometer and chute scale were certified to have been calibrated within 12 mo prior to study initiation.

The randomization schedule was generated in a commercial spreadsheet program (Microsoft Excel, Microsoft, Seattle, WA). While in the chute, each consecutive sequence of four calves were randomly allocated to one of four treatment groups: 1) negative control, 2) positive control (tildipirosin [TIL] to all animals), 3) Whisper-high (TIL only administered to cattle with BRD prediction probabilities above the predetermined threshold for this group), and 4) Whisper-low (TIL only administered to cattle with BRD prediction probabilities above the predetermined threshold for this group).

**Whisper On Arrival Overview**

The Whisper On Arrival machine-learning algorithm was developed through a prior multisite study (i.e., algorithm development study) in which the above data (i.e., heart sounds, lung sounds, rectal temperature, and BW) were captured on all incoming cattle without the application of metaphylaxis. Cattle were followed to closeout and all health, performance, and carcass metrics were used to develop the algorithm tested in the current study (data not shown). For each individual animal, the algorithm generates a probability estimate of developing BRD. Established thresholds then allow for dictating when BRD control therapy is administered (i.e., a probability estimate above the threshold) or withheld (i.e., a probability estimate below the threshold). Therefore, the volume of animals that receive or do not receive BRD control therapy reflects where the threshold lies within the population’s BRD probability distribution.

Among the four treatment groups in the current study, two groups were managed by the Whisper On Arrival system. It was presumed that backgrounders and feedlot producers possess different levels of risk tolerance in forgoing BRD control therapy to proportions of cattle among incoming populations. Therefore, two proprietary thresholds consisting of a conservative (Whisper-high; high diagnostic sensitivity/low diagnostic specificity) and liberal (Whisper-low; low diagnostic sensitivity/high diagnostic specificity) threshold were selected a priori study initiation based on the algorithm generated in the algorithm development study (data not shown). These two thresholds were kept constant across all four study sites.

**Management of Study Population**

All calves were penned by treatment group in open-air, dirt-floor pens whose size varied by study site (TX-2 and NE used 10 hd pens, TX-1 and OK used 70 hd pens). Calves allocated to either Whisper On Arrival-managed group were administered TIL (Zuprevo, Merck Animal Health; 4 mg/kg BW) for BRD control therapy based solely on the algorithm prediction (“Treat” or “Do Not Treat”). Therefore, calves allocated to either of these two treatment groups were housed in pens containing calves that were and were not administered TIL for BRD control.

At all sites, a 3-d post-metaphylactic interval was observed for all treatment groups. Beginning on d 3, all calves were eligible for BRD diagnosis and treatment. Daily observations were performed by trained study personnel masked to treatment group assignments. The BRD case definition across all sites reflected one of two profiles: 1) a CIS of 1 and a rectal temperature ≥40°C or 2) a CIS of 2 or 3 regardless of rectal temperature. Calves observed with a CIS of 4 were euthanized (Table 1). All calves were eligible for BRD treatment up to three times after metaphylaxis administration. The first BRD treatment consisted of florfenicol and flunixin meglumine (Resflor Gold; Merck Animal health; 40 mg florfenicol/kg and 2.2 mg flunixin/kg; subcutaneous [SC] administration). Following a 3-d post-treatment interval, cattle meeting the BRD case definition a second time received enrofloxacin (Baytril 100; Bayer Animal Health, Shawnee, KS; 12.5 mg/kg; SC). Following a 3-d posttreatment interval, if the case definition was met a third time, affected calves were administered oxytetracycline (Biomycin 200; Boehringer Ingelheim Animal Health, Duluth, GA; 9 mg/kg; SC). If more than three rounds of BRD therapy was found to be necessary, the calf was removed from the study.
population, a BW was captured, and treatment was administered, accordingly. However, the calf was considered off-study and all data were collected up to the day of removal. Similarly, each dead calf was individually weighed prior to necropsy and all data were collected up to the day of death.

**Nutritional Programs**

At site TX-1, the same ration was fed for the duration of the 50-d study period. The ration was composed of 44.9% flaked corn, 7.3% corn dried-distillers grain, 17.3% corn wet distillers grain, 18.1% sweet bran, 7.1% corn stalks, and 5.3% supplement on a dry-matter basis. The ration contained Monensin (Rumensin; Zoetis, Kalamazoo, MI; 390 mg/hd/d) and Tylosin (Tylan 100; Elanco, Greenfield, IN; 90 mg/hd/d).

At site TX-2, calves were transitioned across three diets over a 61-d period. The finish ration consisted of 74.5% flaked corn, 8.5% alfalfa hay, 5.5% corn dried-distillers grains, 4% molasses blend, 2% fat, and 5.5% supplement on a DM basis. The finish ration contained Monensin (Rumensin; Zoetis, Kalamazoo, MI; 335 mg/hd/d) and Tylosin (Tylan; Elanco, Greenfield, IN; 100 mg/hd/d).

At site OK, cattle were transitioned across four diets over a 29-d period. The finish ration consisted of 85.9% flaked corn, 3.1% chopped alfalfa, 1.9% sorghum silage, 2.9% choice white grease, and 6.2% supplement on a DM basis. The finish ration contained Monensin (Rumensin; Zoetis, Kalamazoo, MI; 335 mg/hd/d) and Tylosin (Tylan; Elanco, Greenfield, IN; 90 mg/hd/d). Ractopamine (Optaflexx 45; Elanco, Greenfield, IN; 300 mg/hd) was included in the finish ration during the final 29 d on feed.

At site NE, cattle were transitioned across five diets over a 42-d period. The finish ration consisted of 57.4% high-moisture corn, 19.5% Modified distiller’s grains, 19.4% sweat bran, and 3.7% corn stalks on a dry-matter basis. The ration contained Monensin (Rumensin; Zoetis, Kalamazoo, MI; 390 mg/hd/d) and Tylosin (Tylan 100; Elanco, Greenfield, IN; 70 mg/hd/d).

At study conclusion (Days 50 and 60, sites TX-1 and NE, respectively; closeout, sites TX-2 [230 d] and OK [240 d]), individual BWs were captured on all calves still enrolled at that time. Health outcomes were captured at a short-term timepoint (50 or 60 d; all sites) and at closeout (sites TX-2 and OK). Performance outcomes were captured at a short-term timepoint (sites TX-1 and NE) and at closeout (TX-2 and OK). Carcass outcomes were captured for sites TX-2 and OK.

**Statistical Methods**

Due to differences in cattle, feedlot management, pen sizes, and days on feed, data from the four different study sites were analyzed separately. The pen was considered the experimental unit and an alpha of ≤ 0.05 was considered significant. Raw data provided in spreadsheets were formatted for analysis and descriptive statistics were performed. Analyses were performed using linear mixed models (LMM) for a pen-level randomized complete block study design. Models were fitted using binomial (pen-level proportion outcomes), multinomial (ordinal carcass grades) or normal distributions (continuous outcomes), Kenward–Roger degrees of freedom, and Newton–Raphson and Ridging optimization procedures (Proc GLIMMIX SAS 9.4). Before making inferences from non-normal models, overdispersion was evaluated using Pearson chi-square/degrees of freedom (Laplace estimation method). A random intercept term was included in all models to account for the design structure (lack of independence among pens within blocks). Treatment group, coded as four categories, was included as a fixed effect.

**RESULTS**

Across the four sites, 5,120 steer calves were allocated to their respective treatment groups. At the TX-1 site, 7 pens of 70 calves were allocated to each of the four treatment groups, originated from 4 different auction markets, were on study for 50 d, and averaged (range) 286.2 kg (173.3–440 kg) at arrival. At the TX-2 site, 20 pens of 10 calves were allocated to each of the four treatment groups, originated from 2 different auction markets, were on study until closeout (230 d) and averaged (range) 262.6 kg (209.6–435 kg) at arrival. At the OK site, 7 pens of 70 calves were allocated to each of the four treatment groups, originated from 3 different auction markets, were on study until closeout (240 d) and averaged (range) 278.1 kg (180.5–429.1 kg). At the NE site, 10 pens of 10 calves were allocated to each of the four treatment groups, originated from 2 different auction markets, were on study for 60 d and averaged (range) 236.3 kg (172.4–327.5 kg). Across all sites, no calves were removed between the time of removal to the time of processing for BRD or non-BRD syndromes.
Across all four sites, the number of cattle administered BRD control therapy was cumulatively reduced by 11% to 43% between the positive control (100% antibiotic application) and the two Whisper-managed treatment groups. Upon comparing each Whisper-managed group to the positive control, BRD control antibiotic use was reduced by 11% to 18% and 27% to 43% for the Whisper-high and Whisper-low groups, respectively. These outcomes are further displayed (by study site) in Table 2 and are reiterated in Tables 3–7.

Health (short-term duration and closeout timepoints), live performance (short-term duration and closeout timepoints), and carcass outcomes are displayed in Tables 3–7, respectively. Regarding health outcomes at the short-term timepoint (measured at all 4 sites), the positive control and both Whisper-managed groups displayed an improvement ($P \leq 0.05$) in BRD morbidity at three sites (TX-1, TX-2, and OK) but not site NE, BRD 2nd treatments at sites TX-1 and OK but not sites TX-2 and NE, and BRD 3rd treatments at site OK but not sites TX-1, TX-2, and OK compared to the negative control (Table 3). Likewise, regarding performance outcomes measured at the short-term timepoint (sites TX-1 and NE), the positive control and both Whisper-managed groups displayed an improvement ($P \leq 0.05$) in average final weight, average daily gain (ADG; deads-in/deads-out), dry-matter intake, and feed efficiency (deads-in/deads-out) compared to the negative control at site TX-1 but not site NE (Table 3). At closeout (measured at sites TX-2 and OK), the positive control and both Whisper-managed groups displayed an improvement ($P \leq 0.05$) compared to the negative control in BRD morbidity (both sites) and BRD 3rd treatments at site OK but not site TX-2 (Table 5). Regarding closeout performance, the positive control and both Whisper-managed groups displayed an improvement ($P \leq 0.05$) in ADG (deads-in) compared to the negative control at site OK (Table 6). Among carcass outcomes, the positive control and Whisper-high group hot-carcass weights were greater ($P \leq 0.05$) than the negative control at site OK but not site TX-2 (Table 7). No further carcass characteristics were observed to be different ($P > 0.05$; Table 7). Among these respective outcomes at these sites, both Whisper-managed groups displayed no differences ($P > 0.05$) compared to the positive control. No differences ($P > 0.05$) were observed in BRD-related or overall mortality across all sites at either the short-term timepoints or at closeout. At the NE site, no differences ($P > 0.05$) in health or performance were observed across all treatment groups (Tables 3 and 4).

**DISCUSSION**

The objective of this study was to compare health and performance outcomes among a targeted BRD control program based on individualized risk predictions generated by the Whisper On Arrival technology (at two different threshold settings; Whisper-high and Whisper-low), a negative control (i.e., no BRD control drug administration), and a positive control (i.e., conventional BRD control drug practices; 100% application to the targeted population). Across four study sites, the Whisper On Arrival technology reduced BRD control antibiotic use by 11% to 43% without evidence of negative impacts on health, performance, and carcass metrics as compared to the positive control (100% receiving the BRD control drug). Therefore, in this study, the Whisper On Arrival technology showed no difference compared to a conventional BRD control program. However, BRD control antibiotic costs to the producer were reduced across sites and supported judicious antimicrobial use.

Administering an antimicrobial labeled for BRD control is highly effective in reducing the negative effects of BRD (Nickell et al., 2008; Van Donkersgoed et al., 2008b; Nickell and White, 2010; Van Donkersgoed, 2013; Tennant et al., 2014). A recent meta-analysis estimated that the

---

**Table 2. Proportion of BRD control antibiotic application among all treatment groups at each of the four study sites**

| Treatment group | TX-1 | TX-2 | OK  | NE  |
|-----------------|------|------|-----|-----|
| Negative control| 0%   | 0%   | 0%  | 0%  |
| Positive control| 100% | 100% | 100%| 100%|
| Whisper-high    | 89%  | 82%  | 87% | 82% |
| Whisper-low     | 73%  | 70%  | 63% | 57% |

TIL was administered to all calves in the positive control group and only to calves identified as being at risk for developing BRD in both Whisper-managed groups.

Translate basic science to industry innovation
administration of an injectable antibiotic for BRD control reduces the risk of BRD morbidity by 1.5-fold on average within the first 45 d on feed (O’Connor et al., 2019). The decision to administer a BRD control antimicrobial to an incoming population of animals is based on known exposure to risk factors associated with BRD. However, exposure of calf cohorts to these BRD risk factors do not accurately predict BRD cumulative incidence at the group level (Babcock et al., 2013b). This supports recent work that estimates only one in five animals observe a benefit (i.e., reduction in BRD morbidity risk) from BRD control therapy (DeDonder and Apley, 2015). These data indicate

Table 3. Model-adjusted means and standard errors of the means (SEM) for the short-term (50–60 d on feed) health outcomes among each of the four study sites*

| Outcomes                  | Negative control | Positive control | Whisper-high | Whisper-low | P-value† |
|---------------------------|------------------|------------------|-------------|-------------|----------|
|                           | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  |
| TX-1                      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |
| BRD control drug, %       | 0%    |      | 100%  |      | 89.3% | 72.7%|       |      |       |      |       |      |       |      |       |      |
| Days on feed              | 50    |      | 50    |      | 50    |      |       |      |       |      |       |      |       |      |       |      |
| In weight, kg             | 288.9 | 7.3  | 284.9 | 7.3  | 283.5 | 7.3  | 288.5 | 7.3  | 0.43  |
| BRD morbidity             | 18.9% | 3.4% | 5.9%  | 1.5% | 7.6%  | 1.8% | 9.2%  | 2.0% | <0.01 |
| BRD 2nd treatments        | 3.3%  | 1.4% | 0.7%  | 0.4% | 0.6%  | 0.6% | 1.2%  | 0.6% | <0.01 |
| BRD 3rd treatments        | 0.7%  | 0.4% | 0.6%  | 0.4% | 0.7%  | 0.4% | 0.6%  | 0.4% | 0.96  |
| BRD case-fatality         | 3.1%  | 1.8% | 9.7%  | 5.3% | 7.5%  | 4.2% | 6.3%  | 3.5% | 0.54  |
| BRD mortality             | 0.5%  | 0.4% | 0.9%  | 0.5% | 0.5%  | 0.4% | 0.5%  | 0.4% | 0.82  |
| Overall mortality         | 0.6%  | 0.4% | 1.1%  | 0.6% | 0.6%  | 0.5% | 0.9%  | 0.4% | 0.64  |
| OK                        |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |
| BRD control drug, %       | 0%    |      | 100%  |      | 82%   | 69.5%|       |      |       |      |       |      |       |      |       |      |
| Days on feed              | 60    |      | 60    |      | 60    |      |       |      |       |      |       |      |       |      |       |      |
| In weight, kg             | 263.5 | 2.3  | 260.8 | 2.3  | 261.7 | 2.3  | 261.7 | 2.3  | 0.33  |
| BRD morbidity             | 27.7% | 5.5% | 15.9% | 3.9% | 13.4% | 3.5% | 16.4% | 4.0% | <0.01 |
| BRD 2nd treatments        | 6.6%  | 3.2% | 2.4%  | 1.4% | 2.8%  | 1.6% | 4.3%  | 2.2% | 0.08  |
| BRD 3rd treatments        | 2.6%  | 1.5% | 1.1%  | 0.8% | 0.4%  | 0.4% | 2.6%  | 1.5% | 0.17  |
| BRD case-fatality         | 3.6%  | 2.5% | 6.1%  | 4.2% | 0.0%  | 0.0% | 8.8%  | 4.9% | 0.79  |
| BRD mortality             | 1.0%  | 0.7% | 1.0%  | 0.7% | 0.0%  | 0.0% | 1.5%  | 0.9% | 0.96  |
| Overall mortality         | 1.0%  | 0.7% | 1.0%  | 0.7% | 0.0%  | 0.0% | 1.5%  | 0.9% | 0.96  |
| NE                        |       |      |       |      |       |      |       |      |       |      |       |      |       |      |       |      |
| BRD control drug, %       | 0%    |      | 100%  |      | 87.2% | 62.9%|       |      |       |      |       |      |       |      |       |      |
| Days on feed              | 60    |      | 60    |      | 60    |      |       |      |       |      |       |      |       |      |       |      |
| In weight, kg             | 277.6 | 12.7 | 278.5 | 12.7 | 278.1 | 12.7 | 277.6 | 12.7 | 0.89  |
| BRD morbidity             | 17.5% | 7.5% | 8.6%  | 4.2% | 10.3% | 4.8% | 10.2% | 4.9% | <0.01 |
| BRD 2nd treatments        | 4.9%  | 2.2% | 2.2%  | 1.1% | 2.6%  | 1.3% | 4.0%  | 1.9% | 0.04  |
| BRD 3rd treatments        | 3.2%  | 1.2% | 1.1%  | 0.5% | 1.2%  | 0.6% | 2.7%  | 1.0% | 0.04  |
| BRD case-fatality         | 1.7%  | 0.4% | 0.0%  | 0.0% | 0.2%  | 0.8% | 8.8%  | 4.9% | 0.71  |
| BRD mortality             | 0.6%  | 0.4% | 0.0%  | 0.0% | 0.6%  | 0.8% | 0.8%  | 0.4% | 0.68  |
| Overall mortality         | 0.6%  | 0.4% | 0.0%  | 0.0% | 0.6%  | 0.8% | 0.8%  | 0.4% | 0.98  |

*Within each site, the percentage (%) of steers administered BRD control therapy is noted below each respective treatment group. Mixed models with a random effect to account for lack of independence among pens within blocks.
†When overall P-values are ≤ 0.05, means with different superscripts within rows differ significantly (P ≤ 0.05). Not adjusted for multiple comparisons.
that evolving the conventional BRD control management practices to one that targets individuals at greater risk of developing BRD may provide value to stakeholders within the beef supply chain (e.g., producers, veterinarians, retailers, and consumers).

At each of the four study sites, the targeted enrollment population included cattle classified as being of medium to high risk of developing BRD. Given the challenges in using risk factor exposure as a means of predicting BRD incidence at the group level, there is an inherently large degree of variability in potential outcomes (Babcock et al., 2013b). That said, among the negative control treatment groups across sites, BRD morbidity ranged from 18.9% (TX-1) to 34.6% (NE) at the short-term timepoint. However, BRD mortality ranged from 0% (NE) to 1% (TX-2) among the negative controls. Based on these health outcomes, although standardized definitions do not exist, one could argue that all four study populations reflect medium-risk populations rather than high-risk populations. Study populations from prior research designed to study medium/moderate-risk cattle parallel the health outcomes in this study further confirming this observation (Van Donkersgoed et al., 2008b; Tennant et al., 2014). More research is necessary to assess the efficacy of the technology among populations at a greater risk of developing BRD.

Although not unexpected, variability was observed in conventional BRD control efficacy (i.e., efficacy of the positive control compared to the negative control) across study sites. Prior efforts evaluating the body of BRD control literature have observed large ranges in BRD control drug efficacy (DeDonder and Apley, 2015; O’Connor et al., 2019). That said, the traditional BRD control program implemented in this study has previously been shown to be effective (Intervet, 2012; Compiani, 2014; Teixeira et al., 2017; Celestino et al., 2020) and proved to be efficacious at three of the four sites. At one study site (NE), no significant differences were observed in any of the outcome variables compared to the positive control or with either of the Whisper-managed groups. Additionally, among the three sites in which efficacy was observed, the magnitude of the effect (i.e., the number of outcome variables in which statistical differences were identified) differed as well. Given these variances, it is likely prudent to consider the larger system that is being managed and the factors that may influence BRD outcomes. First and foremost, we understand

Table 4. Model-adjusted means for the short-term (50–60 d on feed) performance outcomes among two of the four study sites (TX-1 and NE)*

| Outcomes                        | Negative control | Positive control | Whisper-high | Whisper-low | P-value† |
|---------------------------------|------------------|-----------------|--------------|-------------|---------|
|                                 | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  |
| TX-1                            |       |      |       |      |       |      |       |      |       |      |       |      |       |      |
| BRD control drug application, % | 0%    |      | 100%  |      | 89.3% |      | 72.7% |      |       |      |       |      |       |      |
| Days on feed                    | 50    |      | 50    |      | 50    |      | 50    |      |       |      |       |      |       |      |
| Average in weight, kg           | 288.5 | 5.9  | 288.5 | 5.9  | 286.2 | 5.9  | 291.2 | 5.9  |       |      |       |      |       |      |
| Average final weight, kg        | 332.5 | 8.5  | 342.5 | 8.5  | 338.8 | 8.5  | 343.4 | 8.5  |       |      |       |      |       |      |
| ADG, deads-out; kg/d            | 0.9a  | 0.1  | 1.1b  | 0.1  | 1.1b  | 0.1  | 1.1b  | 0.1  |       |      |       |      |       |      |
| ADG, deads-in; kg/d             | 0.8a  | 0.1  | 1.0b  | 0.1  | 1.0b  | 0.1  | 1.0b  | 0.1  |       |      |       |      |       |      |
| Mean daily DMI, kg/d            | 6.6a  | 0.2  | 7.0b  | 0.2  | 7.0b  | 0.2  | 7.0b  | 0.2  |       |      |       |      |       |      |
| G:F, deads-out                  | 0.13a | 0.01 | 0.16b | 0.01 | 0.1524b| 0.01 | 0.1498b| 0.01 |       |      |       |      |       |      |
| G:F, deads-in                   | 0.13  | 0.01 | 0.15  | 0.01 | 0.15  | 0.01 | 0.14  | 0.01 |       |      |       |      |       |      |
| NE                              |       |      |       |      |       |      |       |      |       |      |       |      |       |      |
| BRD control drug application, % | 0%    |      | 100%  |      | 82%   |      | 57%   |      |       |      |       |      |       |      |
| Days on feed                    | 60    |      | 60    |      | 60    |      | 60    |      |       |      |       |      |       |      |
| Average in weight, kg           | 234.5 | 2.3  | 235.9 | 2.3  | 238.1 | 2.3  | 235.9 | 2.3  |       |      |       |      |       |      |
| Average final weight, kg        | 321.6 | 7.7  | 324.8 | 7.7  | 325.7 | 7.7  | 319.8 | 7.7  |       |      |       |      |       |      |
| ADG, deads-out; kg/d            | 1.4   | 0.1  | 1.5   | 0.1  | 1.4   | 0.1  | 1.4   | 0.1  |       |      |       |      |       |      |
| ADG, deads-in; kg/d             | 0.4   | 0.5  | 0.5   | 0.5  | 0.2   | 0.5  | 0.4   | 0.5  |       |      |       |      |       |      |
| Mean daily DMI, kg/d            | 7.0   | 0.6  | 7.1   | 0.6  | 6.9   | 0.6  | 7.2   | 0.6  |       |      |       |      |       |      |
| G:F, deads-out                  | 0.20  | 0.03 | 0.21  | 0.03 | 0.21  | 0.03 | 0.21  | 0.03 |       |      |       |      |       |      |
| G:F, deads-in                   | 0.07  | 0.08 | 0.08  | 0.08 | 0.03  | 0.08 | 0.06  | 0.08 |       |      |       |      |       |      |

*Within each site, the percentage (%) of steers administered BRD control therapy is noted below each respective treatment group. Mixed models with a random effect to account for lack of independence among pens within blocks.
† When overall P-values are ≤ 0.05, means with different superscripts within rows differ significantly (P ≤ 0.05). Not adjusted for multiple comparisons.
‡Deads-in/deads-out calculations reflect the inclusion (deads-in) or exclusion (deads-out) of cattle that died during the study duration.
that current BRD diagnostic modalities are significantly flawed (due to the subjective nature of clinical signs) and likely distort the true cumulative incidence of BRD morbidity (White and Renter, 2009; Timsit et al., 2016). For example, the NE site observed the highest degree of morbidity within the negative control group (34.6%); however, virtually no mortality was observed during that 60-d study duration. Therefore, one possible explanation for the outlying outcomes at the NE site is that those respective study personnel may be more sensitive (and subsequently less specific) in their BRD detection efforts. Additional parameters that likely influence the magnitude of BRD include prepartum (Van Donkersgoed et al., 1995; Van Eenennaam et al., 2014), preweaning (Hanzlicek et al., 2013; Murray et al., 2016), weaning (Taylor et al., 2020), and postweaning factors (Cernicchiaro et al., 2012a, 2012b, 2012c). Therefore, although there may be scenarios where drug efficacy is specifically associated with a lack of BRD reduction between the positive and control group, it is likely that there are additional factors at play that we are unable to currently measure and subsequently manage in a study design like that implemented in the current study. More research is necessary to determine if animal and/or cohort physiological profiles impact response to current BRD control measures.

Variability was observed across sites relative to the proportion of animals receiving BRD control therapy in both Whisper On Arrival-managed groups. Given likely differences in the magnitude of BRD risk factor exposure from cohort to cohort, it is probable that the actual BRD risk profile of each group will also vary. Therefore, it was not unexpected to observe differences in the proportion of animals receiving BRD control therapy, not only across sites, but also across different lots within a site (data not shown). In practice, the threshold setting for the Whisper On Arrival system is dictated by the user and may be modified based on their perceived risk classification of each incoming lot. However, more research is necessary to determine if the Whisper On Arrival threshold can be optimized based on the quantified magnitude of BRD risk factor exposure.

The original Whisper system (Whisper Veterinary Stethoscope) is applied exclusively to sick cattle to estimate lung health at the time of BRD diagnosis (DeDonder, 2010; Timsit et al., 2016; Zeineldin, 2016; Baruch et al., 2019). In contrast, the Whisper On Arrival technology predicts the likelihood of a future clinical BRD event (rather than confirm a diagnosis on a sick animal) and is applied to cattle at the time of arrival. Cattle at feedlot arrival, compared to the clinically ill population, reflect a population experiencing a different physiological and disease state.

| Outcomes                  | Negative control | Positive control | Whisper-high | Whisper-low | P-value† |
|---------------------------|------------------|------------------|--------------|-------------|----------|
|                           | Mean             | Mean             | Mean         | Mean        | P-value† |
| TX-2                      |                  |                  |              |             |          |
| BRD control drug application, % | 0%               | 100%             | 82%          | 69.5%       |          |
| Day on feed               | 233              | 233              | 233          | 233         |          |
| BRD morbidity             | 28.3%            | 5.5%             | 17.5%        | 4.1%        | 15.0%    | 3.7%    | 18.0%    | 4.2%    | <0.01   |
| BRD 2nd treatments        | 7.9%             | 3.2%             | 4.5%         | 2.0%        | 4.0%     | 1.9%    | 6.2%     | 2.6%    | 0.26    |
| BRD 3rd treatments        | 2.9%             | 1.7%             | 1.4%         | 1.0%        | 0.7%     | 0.6%    | 2.9%     | 1.7%    | 0.20    |
| BRD case-fatality         | 5.3%             | 3.0%             | 5.6%         | 3.8%        | 6.5%     | 4.4%    | 10.8%    | 5.1%    | 0.75    |
| BRD mortality             | 1.5%             | 0.9%             | 1.0%         | 0.7%        | 1.0%     | 0.7%    | 2.5%     | 1.1%    | 0.70    |
| Overall mortality         | 1.9%             | 1.1%             | 1.5%         | 0.9%        | 1.9%     | 1.1%    | 3.4%     | 1.5%    | 0.57    |

OK

| Outcomes                  | Negative control | Positive control | Whisper-high | Whisper-low | P-value† |
|---------------------------|------------------|------------------|--------------|-------------|----------|
|                           | Mean             | Mean             | Mean         | Mean        | P-value† |
| BRD control drug application, % | 0%               | 100%             | 87.2%        | 62.9%       |          |
| Day on feed               | 240              | 240              | 240          | 240         |          |
| BRD morbidity             | 22.0%            | 6.27%            | 11.5%        | 3.8%        | 13.2%    | 4.3%    | 13.4%    | 4.3%    | <0.01   |
| BRD 2nd treatments        | 6.4%             | 2.2%             | 3.5%         | 1.3%        | 3.5%     | 1.3%    | 5.0%     | 1.8%    | 0.06    |
| BRD 3rd treatments        | 4.2%             | 1.3%             | 1.8%         | 0.7%        | 1.6%     | 0.7%    | 3.3%     | 1.1%    | 0.04    |
| BRD case-fatality         | 3.2%             | 1.6%             | 1.5%         | 1.4%        | 1.3%     | 1.3%    | 6.3%     | 2.7%    | 0.33    |
| BRD mortality             | 1.2%             | 0.5%             | 0.2%         | 0.2%        | 0.4%     | 0.3%    | 1.2%     | 0.5%    | 0.20    |
| Overall mortality         | 1.8%             | 0.6%             | 1.0%         | 0.5%        | 1.2%     | 0.5%    | 1.8%     | 0.6%    | 0.63    |

*Mixed models with a random effect to account for lack of independence among pens within blocks.
†When overall P-values are ≤ 0.05, means with different superscripts within rows differ significantly (P ≤ 0.05). Not adjusted for multiple comparisons.
Table 6. Model-adjusted means for the closeout performance outcomes among two of the four study sites (TX-2 and OK)*

| Outcomes                              | Negative control | Positive control | Whisper-high | Whisper-low | P-value† |
|---------------------------------------|------------------|------------------|--------------|-------------|----------|
|                                       | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  | Mean  | SEM  |        |
| TX-2                                  |       |      |       |      |       |      |       |      |        |
| BRD control drug application, %       | 0%    | 233  | 100%  | 233  | 82%   | 233  | 69.5%  | 233  |        |
| Day on feed                           |       |      |       |      |       |      |       |      |        |
| Average in weight, kg                | 263.5 | 2.3  | 268.8 | 2.3  | 261.7 | 2.3  | 261.7  | 2.3  | 0.33    |
| Average final weight, kg             | 597.4 | 7.2  | 601.5 | 7.2  | 611.9 | 7.2  | 597.8  | 7.2  | 0.13    |
| ADG, deads-out; kg/d                  | 1.5   | 0.0  | 1.5   | 0.0  | 1.5   | 0.0  | 1.5    | 0.0  | 0.65    |
| ADG, deads-in                         | 1.4   | 0.0  | 1.5   | 0.0  | 1.4   | 0.0  | 1.5    | 0.0  | 0.45    |
| Mean daily DMI                        | 8.1   | 0.1  | 8.3   | 0.1  | 8.4   | 0.1  | 8.1    | 0.1  | 0.18    |
| G:F, deads-out                        | 0.18  | 0.003| 0.18  | 0.003| 0.18  | 0.003| 0.18   | 0.003| 0.62    |
| G:F, deads-in                         | 0.17  | 0.003| 0.17  | 0.003| 0.17  | 0.003| 0.17   | 0.003| 0.94    |
| OK                                    |       |      |       |      |       |      |       |      |        |
| BRD control drug application, %       | 0%    | 240  | 100%  | 240  | 87.2% | 240  | 62.9%  | 240  |        |
| Days on feed                          |       |      |       |      |       |      |       |      |        |
| Average in weight, lbs                | 281.8 | 12.7 | 282.3 | 12.7 | 280.9 | 12.7 | 281.4  | 12.7 | 0.51    |
| Average final weight, pen; lbs        | 631.4 | 8.2  | 640.9 | 8.2  | 640.0 | 8.2  | 642.7  | 8.2  | 0.13    |
| ADG, deads-out; kg/d                  | 1.5   | 0.1  | 1.5   | 0.1  | 1.5   | 0.1  | 1.5    | 0.1  | 0.17    |
| ADG, deads-in; kg/d                   | 1.36  | 0.05 | 1.45  | 0.05 | 1.46  | 0.05 | 1.43   | 0.05 | 0.05    |
| Mean daily DMI                        | 8.3   | 0.2  | 8.3   | 0.2  | 8.6   | 0.2  | 8.4    | 0.2  | 0.06    |
| G:F, deads-out                        | 0.18  | 0.002| 0.18  | 0.002| 0.18  | 0.002| 0.18   | 0.002| 0.18    |
| G:F, deads-in                         | 0.16  | 0.003| 0.17  | 0.003| 0.17  | 0.003| 0.17   | 0.003| 0.16    |

* A 4% shrink was applied to closeout weights. Mixed models with a random effect to account for lack of independence among pens within blocks.
† When overall P-values are ≤ 0.05, means with different superscripts within rows differ significantly (P ≤ 0.05). Not adjusted for multiple comparisons.
‡ Deads-in/deads-out calculations reflect the inclusion (deads-in) or exclusion (deads-out) of cattle that died during the study duration.

(Hanzlicek et al., 2010; Baruch et al., 2019). Therefore, permutations of lung sound data and additional information (heart sound metrics, rectal temperature, and BW) were found to be necessary to optimize the robustness of the predicted estimate (data not shown). Additionally, in contrast to the Whisper Veterinary Stethoscope technology, the Whisper On Arrival system utilizes a novel sound capture device that is more conducive to the ergonomics and safety profile necessary for processing incoming cattle. Nonetheless, given that the Whisper On Arrival system represents an additional processing event, costs associated with additional labor, time, and cost of the technology must be evaluated by the producer.

Beef producers continuously search for cost management opportunities, while veterinarians strive to not only support their client’s economic endeavors but also sustain the tools (e.g., antibiotics) implemented to reduce disease pressure within production systems. Both entities are also widely cognizant of market factors that may affect producer demand. The Whisper On Arrival technology was developed to 1) optimize the cost associated with this practice by individually identifying cattle at risk of developing BRD, subsequently providing actionable data for the user leading to a decision to administer a BRD control antimicrobial or forgo therapy and 2) support judicious antimicrobial use. Across four study sites, the Whisper On Arrival technology reduced BRD control antibiotic use 11% to 43% without negative impacts on health, performance, and carcass metrics as compared to the positive control (100% receiving the BRD control drug). Therefore, the Whisper On Arrival technology maintained the benefits of a conventional BRD control program while reducing antibiotic costs to the producer and supporting judicious antimicrobial use.

ACKNOWLEDGMENTS

Allflex Livestock Intelligence (ALI) is a subsidiary of Merck Animal Health (MAH). Merck Animal Health fully funded the study. Coauthors J.N. and J.H. (employees of ALI and MAH, respectively) provided study design and monitoring efforts. Coauthors D.R. and D.A. provided data management and analysis services.

Conflict of interest statement. None declared.
### Table 7. Model-adjusted means for the carcass outcomes among two of the four study sites (TX-2 and OK)*

| Outcomes                  | TX-2                | OK                 |
|---------------------------|---------------------|--------------------|
|                           | Negative control    | Positive control   | Whisper-high       | Whisper-low       |
|                           | Mean       SEM       | Mean       SEM       | Mean       SEM       | Mean       SEM       |
| BRD control drug          |                      |                    |                    |                    |
| application, %            | 0%               4.0  | 100%              4.0  | 82%               4.0  | 69.5%              4.0  |
| Hot carcass weight, kg    | 376.4         4.0  | 380.9              4.0  | 385.5             4.0  | 380.0             4.0  | 0.45               |
| Yield, %                  | 60.8            0.3  | 61.3               0.3  | 61.2              0.3  | 61.3              0.3  | 0.54               |
| Ribeye area               | 14.7            0.2  | 14.3               0.2  | 14.6              0.2  | 14.4              0.2  | 0.31               |
| Marbling                  | 475             7.6  | 486                7.6  | 482               7.6  | 473               7.6  | 0.57               |
| Backfat                   | Not reported     NR  | NR                 | NR                | NR                | NR                |                    |
| Calculated yield grade    | 2.8             0.1  | 2.9                0.1  | 2.8               0.1  | 2.8               0.1  | 0.82               |
| Yield grade               | % of treatment group (count) |                    |                    |                    |                    |                    |
| 1                         | 9.9% (13)        | 9.7% (13)          | 14.0%             (19) | 10.4%             (14) | N = 536^            |
| 2                         | 59.5% (78)       | 45.5%              (61) | 44.1%             (60) | 46.7%             (63) |                    |
| 3                         | 23.7% (31)       | 34.3%              (46) | 36.0%             (49) | 35.6%             (48) |                    |
| 4                         | 6.9% (9)         | 8.2%               (11) | 4.4%              (6)  | 7.4%              (10) |                    |
| 5                         | 0.0% (0)         | 2.2%               (3)  | 1.5%              (2)  | 0.0%              (0)  |                    |
| Quality grade             | % of treatment group (count) |                    |                    |                    |                    |                    |
| Prime                     | 5.3% (7)         | 5.2%               (7)  | 1.5%              (2)  | 1.5%              (2)  | N = 537            |
| Choice                    | 76.3% (100)      | 76.3%              (103) | 82.4%             (112) | 84.4%             (114) |                    |
| Select                    | 18.3% (24)       | 18.5%              (25) | 15.4%             (21) | 13.3%             (18) |                    |
| Other                     | 0.0% (0)         | 0.0%               (0)  | 0.7%              (1)  | 0.7%              (1)  |                    |
| Hot carcass weight, kg    | 410.0           3.5  | 415.5              3.5  | 417.8             3.5  | 411.4             3.5  | 0.03               |
| Yield, %                  | 65.2            0.4  | 65.0               0.4  | 65.4              0.4  | 64.3              0.4  | 0.14               |
| Ribeye area               | 14.8            0.2  | 14.8               0.2  | 15.0              0.2  | 14.6              0.2  | 0.08               |
| Marbling                  | 515             10.3  | 502                10.3  | 502               10.3  | 503               10.3  | 0.31               |
| Backfat                   | 0.7             0.0  | 0.7                0.0  | 0.7               0.0  | 0.7               0.0  | 0.76               |
| Calculated yield grade    | 3.2             0.1  | 3.3                0.1  | 3.2               0.1  | 3.3               0.1  | 0.50               |
| Yield grade               | % of treatment group (count) |                    |                    |                    |                    |                    |
| 1                         | 8.5% (39)        | 9.2%               (44) | 15.2%             (72) | 7.3%              (34) | N = 1,880          |
| 2                         | 34.4% (158)      | 30.5%              (146) | 30.8%             (146) | 32.6%             (152) |                    |
| 3                         | 37.0% (170)      | 38.8%              (186) | 35.2%             (167) | 36.8%             (172) |                    |
| 4                         | 17.8% (82)       | 18.8%              (90) | 15.8%             (75) | 19.5%             (91) |                    |
| 5                         | 2.4% (11)        | 2.7%               (13) | 3.0%              (14) | 3.9%              (18) |                    |
| Quality grade             | % of treatment group (count) |                    |                    |                    |                    |                    |
| Prime                     | 6.1% (28)        | 4.6%               (22) | 16.7%             (79) | 4.5%              (21) | N = 1,879          |
| Choice                    | 82.6% (380)      | 84.6%              (405) | 74.6%             (353) | 86.9%             (406) |                    |
| Select                    | 10.7% (49)       | 10.9%              (52) | 8.5%              (40)  | 8.6%              (40)  |                    |
| Other                     | 0.7% (3)         | 0.0%               (0)  | 0.2%              (1)  | 0.0%              (0)  |                    |

*Mixed models with a random effect to account for lack of independence among pens within blocks.

†When overall P-values are ≤ 0.05, means with different superscripts within rows differ significantly (P ≤ 0.05). Not adjusted for multiple comparisons.

‡Final carcass counts reflected in the analysis are less than actual enrollment numbers due to inability to retrieve data from all lots.

### REFERENCES

Apley, M. 2006. Bovine respiratory disease: pathogenesis, clinical signs, and treatment in lightweight calves. Vet. Clin. North Am. Food Anim. Pract. 22:399–411. doi:10.1016/j.cvfa.2006.03.009

Babcock, A. H., N. Cernichiaro, B. J. White, S. R. Dubnicka, D. U. Thomson, S. E. Ives, H. M. Scott, G. A. Milliken, and D. G. Renter. 2013a. A multivariable assessment quantifying effects of cohort-level factors associated with combined mortality and culling risk in cohorts of U.S. commercial feedlot cattle. Prev. Vet. Med. 108:38–46. doi:10.1016/j.prevetmed.2012.07.008

Babcock, A. H., D. G. Renter, B. J. White, S. R. Dubnicka, and H. M. Scott. 2010. Temporal distributions of respiratory disease events within cohorts of feedlot cattle and associations with cattle health and performance indices. Prev. Vet. Med. 97:198–219. doi:10.1016/j.prevetmed.2010.09.003
Babcock, A. H., B. J. White, D. G. Renter, S. R. Dubnicka, and H. M. Scott. 2013b. Predicting cumulative risk of bovine respiratory disease complex (BRDC) using feedlot arrival data and daily morbidity and mortality counts. Can. J. Vet. Res. 77:33–44.

Baptiste, K. E., and N. C. Kyvsgaard. 2017. Do antimicrobial mass medications work? A systematic review and meta-analysis of randomised clinical trials investigating antimicrobial prophylaxis or metaphylaxis against naturally occurring bovine respiratory disease. Pathog Dis. 75:1–12. doi: 10.1093/femspd/ftx083

Baruch, J., N. Cernicchiaro, C. A. Cull, K. F. Lechtenberg, J. S. Nickell, and D. G. Renter. 2019. Performance of multiple diagnostic methods in assessing the progression of bovine respiratory disease in calves challenged with infectious bovine rhinotracheitis virus and Mannheimia haemolytica. J. Anim. Sci. 97:2357–2367. doi:10.1093/jas/skz107

CDC. 2019. Antibiotic resistance threats in the United States, 2019. US Department of Health and Human Services (ed.) No. 2019. Available from http://dx.doi.org/10.15620/cdc82532

Celestino, M. L., L. Fernandes, P. R. Menta, D. Paiva, T. L. Ribeiro, T. Silva, T. R. Bilby, R. C. Neves, M. A. Ballou, and V. S. Machado. 2020. The effect of metaphylactic use of tildipirosin for the control of respiratory disease in long-distance transported dairy calves. Front. Vet. Sci. 7:632. doi: 10.3389/fvets.2020.00632

Cernicchiaro, N., D. G. Renter, B. J. White, A. H. Babcock, and J. T. Fox. 2012a. Associations between weather conditions during the first 45 days after feedlot arrival and daily respiratory disease risks in autumn-placed feeder cattle in the United States. J Anim Sci. 90:1328–1337. doi: 10.2527/jas.2011–4657

Cernicchiaro, N., B. J. White, D. G. Renter, A. H. Babcock, L. Kelly, and R. Slattery. 2012b. Associations between the distance traveled from sale barns to commercial feedlots in the United States and overall performance, risk of respiratory disease, and cumulative mortality in feeder cattle during 1997 to 2009. J Anim Sci. 90:1929–1939. doi: 10.2527/jas.2011–4599

Cernicchiaro, N., B. J. White, D. G. Renter, A. H. Babcock, L. Kelly, and R. Slattery. 2012c. Effects of body weight loss during transit from sale barns to commercial feedlots on health and performance in feeder cattle cohorts arriving to feedlots from 2000 to 2008. J Anim Sci. 90:1940–1947. doi: 10.2527/jas.2011–4600

Compiani, R. B. G., M. Bonfanti, D. Fucci, G. Pisoni, S. Jottini, S. Torres. 2014. Comparison of tildipirosin and tulathromycin for control of bovine respiratory disease in high-risk beef heifers. Bovine Practitioner. 48:114–119. doi: 10.21423/bovine-vol48no2p114–119

Dean, W. R. M., W. A., H. M. Scott. 2011. The role of trust and moral obligation in beef cattle feedlot veterinarians’ contingent adoption of antibiotic metaphylaxis recommendations. Int. J. Soc. Agr. Food. 18:104–120. doi:10.48416/ijsaf.v18i2.249

DeDonder, K. D., and M. D. Apley. 2015. A review of the expected effects of antimicrobials in bovine respiratory disease treatment and control using outcomes from published randomized clinical trials with negative controls. Vet. Clin. North Am. Food Anim. Pract. 31:97–111. vii. doi:10.1016/j.cvfa.2014.11.003

DeDonder, K., D. U. Thomson, G. H. Loneragan, T. Noftsinger, W. Taylor, M. D. Apley. 2010. Lung auscultation and rectal temperature as a predictor of lung lesions and bovine respiratory disease treatment outcome in feedyard cattle. Bovine Practitioner. 44:146–153. doi:10.21423/bovine-vol44no2p146–153

Dennis E. J., D. L. Pendell, D. G. Renter, and T. C. Schroeder. 2018. Value of arrival metaphylaxis in U.S. cattle industry. J. Agric. Resour. Econ. 43:233–250. doi:10.22004/ag.econ.273448

FASS. 2010. Federation of Animal Science Societies: guide for the care and use of agricultural animals in research and teaching. Available from http://www.fass.org

FDA. 2018. Supporting antimicrobial stewardship in veterinary settings: goals for fiscal years 2019–2023. US Food and Drug Administration. Available from https://www.fda.gov/media/115776/download.

Gardner, B. A., H. G. Dolezel, L. K. Bryant, F. N. Owens, and R. A. Smith. 1999. Health of finishing steers: effects on performance, carcass traits, and meat tenderness. J. Anim. Sci. 77:3168–3175. doi:10.2527/1999.77123168x

Hanzlicek, G. A., D. R. Renter, B. J. White, B. A. Wagner, D. A. Dargatz, M. W. Sanderson, H. M. Scott, and R. E. Larson. 2013. Management practices associated with the rate of respiratory tract disease among preweaned beef calves in cow-calf operations in the United States. J. Am. Vet. Med. Assoc. 242:1271–1278. doi:10.2460/jvma.242.9.1271

Hanzlicek, G. A., B. J. White, D. Mosier, D. G. Renter, and D. E. Anderson. 2010. Serial evaluation of physiologic, pathological, and behavioral changes related to disease progression of experimentally induced Mannheimia haemolytica pneumonia in postweaned calves. Am. J. Vet. Res. 71:359–369. doi:10.2460/ajvr.71.3.359

Intervet, I. 2012. Freedom of Information Summary; Original New Animal Drug Application; NADA 141–334; Zuprevo; Tildipirosin; 18% Injectable Solution; Beef and Non-Lactating Dairy Cattle. Available from https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoil892

Murray, C. F., L. J. Fick, E. A. Pajor, H. W. Barkema, M. D. Jelinski, and M. C. Windleyer. 2016. Calf management practices and associations with herd-level morbidity and mortality on beef cow-calf operations. Animal. 10:468–477. doi:10.1017/S1751731115002062

Nickell, J. S., B. J. White, R. L. Larson, D. A. Blasi, and D. G. Renter. 2008. Comparison of short-term health and performance effects related to prophylactic administration of tulathromycin versus tilmicosin in long-hauled, highly stressed beef stocker calves. Vet. Ther. 9:147–156.

Nickell, J. S., and B. J. White. 2010. Metaphylactic antimicrobial therapy for bovine respiratory disease in stocker and feedlot cattle. Vet. Clin. North Am. Food Anim. Pract. 26:285–301. doi:10.1016/j.cvfa.2010.04.006

O’Connor, A. M., D. Hu, S. C. Totton, N. Scott, C. B. Winder, B. Wang, C. Wang, J. Glanville, H. Wood, B. White, et al. 2019. A systematic review and network meta-analysis of bacterial and viral vaccines, administered at or near arrival at the feedlot, for control of bovine respiratory disease in beef cattle. Anim Health Res Rev. 20:143–162. doi:10.1017/S1466252319000288
Perino, L. J., and M. D. Apley. 1998. Clinical trial design in feedlots. Vet. Clin. North Am. Food Anim. Pract. 14:343–365. doi:10.1016/0749-0720(15)30258-9
Taylor, J. D., R. W. Fulton, T. W. Lehenbauer, D. L. Step, and A. W. Confer. 2010. The epidemiology of bovine respiratory disease: What is the evidence for predisposing factors? Can. Vet. J. 51:1095–1102.
Taylor, J. D., R. W. Fulton, T. W. Lehenbauer, D. L. Step, and A. W. Confer. 2010. The epidemiology of bovine respiratory disease: what is the evidence for preventive measures? Can. Vet. J. 51:1351–1359.
Taylor, J. D., J. N. Gilliam, G. Mourer, and C. Stansberry. 2020. Comparison of effects of four weaning methods on health and performance of beef calves. Animal 14:161–170. doi:10.1017/S1751731119001228
Teixeira, A. G. V., J. A. A. McArt, and R. C. Bicalho. 2017. Efficacy of tildipirosin metaphylaxis for the prevention of respiratory disease, otitis and mortality in pre-weaned Holstein calves. Vet. J. 219:44–48. doi:10.1016/j.tvjl.2016.12.004
Tennant, T. C., S. E. Ives, L. B. Harper, D. G. Renter, and T. E. Lawrence. 2014. Comparison of tulathromycin and tilmicosin on the prevalence and severity of bovine respiratory disease in feedlot cattle in association with feedlot performance, carcass characteristics, and economic factors. J. Anim. Sci. 92:5203–5213. doi:10.2527/jas.2014-7814
Timsit, E., N. Dendukuri, I. Schiller, and S. Buczinski. 2016. Diagnostic accuracy of clinical illness for bovine respiratory disease (BRD) diagnosis in beef cattle placed in feedlots: a systematic literature review and hierarchical Bayesian latent-class meta-analysis. Prev. Vet. Med. 135:67–73. doi:10.1016/j.prevetmed.2016.11.006
Van Donkersgoed, J., J. Berg, and S. Hendrick. 2008. Comparison of florfenicol and tulathromycin for the treatment of undifferentiated fever in Alberta feedlot calves. Vet. Ther. 9:275–281.
Van Donkersgoed, J., C. Guenther, B. N. Evans, A. A. Potter, and R. J. Harland. 1995. Effects of various vaccination protocols on passive and active immunity to Pasteurella haemolytica and Haemophilus somnus in beef calves. Can. Vet. J. 36:424–429.
Van Donkersgoed, J., J. Merrill, and S. Hendrick. 2008. Comparative efficacy of tilmicosin versus tulathromycin as a metaphylactic antimicrobial in feedlot calves at moderate risk for respiratory disease. Vet. Ther. 9:291–297.
Van Donkersgoed, J., and J. K. Merrill. 2013. Efficacy of tilmicosin and tildipirosin for on-arrival treatment of bovine respiratory disease in fall-placed feedlot calves in western Canada. Bovine Practitioner. 47:146–151. doi:10.21423/bovine-vol47no2p146-151
Van Eenennaam, A., H. Neibergs, C. Seabury, J. Taylor, Z. Wang, E. Scraggs, R. D. Schnabel, J. Decker, A. Wojtowicz, S. Aly, et al. 2014. Results of the BRD CAP project: progress toward identifying genetic markers associated with BRD susceptibility. Anim Health Res Rev. 15:157–160. doi: 10.1017/S1466252314000231
Vogel, G. J., S. B. Laudert, A. Zimmermann, C. A. Guthrie, G. D. Mechor, and G. M. Moore. 1998. Effects of tilmicosin on acute undifferentiated respiratory tract disease in newly arrived feedlot cattle. J. Am. Vet. Med. Assoc. 212:1919–1924. Available from https://www.cabdirect.org/cabdirect/abstract/19982215929
White, B. J., and D. G. Renter. 2009. Bayesian estimation of the performance of using clinical observations and harvest lung lesions for diagnosing bovine respiratory disease in post-weaned beef calves. J. Vet. Diagn. Invest. 21:446–453. doi:10.1177/104063870902100405
Zeineldin, M. M., Y. M. Abd El-Raof, H. A. El-attar, and M. M. Ghanem. 2016. Lung ultrasonography and computer-aided scoring system as a diagnostic aid for bovine respiratory disease in feedlot cattle. Global Veterinaria. 17:588–594. Available from https://ssrn.com/abstract=2970595